A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA.hy926 endothelial cell line

Biol Res. 2009;42(3):377-89. Epub 2009 Nov 2.


Angiogenesis, the development of new capillary vessels, has a host of clinical manifestations. The identification of agents that increase or decrease angiogenesis is of great pharmaceutical interest. Classically, in vitro angiogenesis utilizes human umbilical vein endothelial cells (HUVEC) grown in matrigel. This valid and simple method has the drawbacks that each cell population is distinct and the constraint of obtaining primary source material. Herein we utilize the established EA.hy926 endothelial cell line as our model for in vitro angiogenesis and present a novel formula to quantify endothelial cell remodeling to identify pro- and anti-angiogenic agents. Furthermore, our technique details the procedures to identify and quantify compounds that have the capacity to generate pro- or anti-angiogenic factors when given to non-endothelial cells, which we define herein as angiogenic potential. In conclusion, we propose a novel formula that we are confident accurately reflects the degree of in vitro angiogenesis allowing the quantification of prospective angiogenic compounds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inducing Agents / pharmacology*
  • Cell Line
  • Collagen / pharmacology*
  • Drug Combinations
  • Drug Evaluation, Preclinical
  • Endothelial Cells / drug effects*
  • Humans
  • Laminin / pharmacology*
  • Neovascularization, Physiologic / drug effects*
  • Neovascularization, Physiologic / physiology
  • Proteoglycans / pharmacology*


  • Angiogenesis Inducing Agents
  • Drug Combinations
  • Laminin
  • Proteoglycans
  • matrigel
  • Collagen